Department of Molecular & Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool L693GE, UK.
Medical School, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
Toxicol Sci. 2020 Nov 1;178(1):115-126. doi: 10.1093/toxsci/kfaa128.
Amoxicillin-clavulanate is the most common cause of idiosyncratic drug-induced liver injury (DILI). Drug-specific CD4+ T cells have been detected in patients with DILI, suggestive of an immune etiology. Furthermore, genetic associations including the human leucocyte antigen (HLA) DRB115:01-DQB106:02 haplotype influence susceptibility. Amoxicillin forms protein adducts that are postulated to activate T cells, by conjugating with lysine residues. However, a role for such adducts has not been described. This study aimed to (1) investigate whether amoxicillin-modified HLA-DRB115:01-DQB106:02 binding peptides selectively activate DILI patient T cells and (2) define the nature of the T-cell response with respective to antigen structure. Peptides carrying lysine residues for amoxicillin binding in positions (KP) 2-6 and anchors for the HLA-DRB115:01-DQB106:02 haplotype were designed. The amoxicillin-modified peptides were characterized by mass spectrometry prior to culturing with patient peripheral blood mononuclear cell. T-cell clones were then tested for specificity with amoxicillin, unmodified- and amoxicillin-modified peptides, and structural variants. Amoxicillin-modified KP-2 and KP-3 peptide-specific CD4+ clones proliferated and secreted interferon gamma (IFN-γ), interleukin (IL)-10, perforin and/or IL-17/IL-22 in a dose-dependent manner and displayed no cross-reactivity with amoxicillin, unmodified peptide or with positional derivatives. The T cells response was HLA class II restricted and the amoxicillin-modified peptides bound selectively to HLA-DRB115:01 and/or DQB106:02. To conclude, we show that amoxicillin-modified peptides bind to both components of the risk haplotype to stimulate DILI patient T cells and describe the importance of the position of nucleophilic lysine residue in the HLA binding peptide sequence.
阿莫西林克拉维酸是最常见的导致药物性肝损伤(DILI)的原因。在 DILI 患者中已经检测到药物特异性 CD4+T 细胞,提示其具有免疫病因。此外,包括人类白细胞抗原(HLA)DRB115:01-DQB106:02 单体型在内的遗传关联影响易感性。阿莫西林形成的蛋白加合物被认为通过与赖氨酸残基结合来激活 T 细胞。然而,尚未描述这种加合物的作用。本研究旨在(1)研究阿莫西林修饰的 HLA-DRB115:01-DQB106:02 结合肽是否选择性地激活 DILI 患者的 T 细胞,以及(2)根据抗原结构定义 T 细胞反应的性质。设计了在位置(KP)2-6 处携带与阿莫西林结合的赖氨酸残基和 HLA-DRB115:01-DQB106:02 单体型的锚点的携带赖氨酸残基的肽。在与患者外周血单核细胞共培养之前,通过质谱法对阿莫西林修饰的肽进行了表征。然后,用阿莫西林、未修饰的和阿莫西林修饰的肽以及结构变体对 T 细胞克隆进行特异性测试。阿莫西林修饰的 KP-2 和 KP-3 肽特异性 CD4+克隆以剂量依赖性方式增殖并分泌干扰素γ(IFN-γ)、白细胞介素(IL)-10、穿孔素和/或 IL-17/IL-22,并且与阿莫西林、未修饰的肽或位置衍生物无交叉反应。T 细胞反应受 HLA Ⅱ类限制,阿莫西林修饰的肽选择性结合 HLA-DRB115:01 和/或 DQB106:02。总之,我们表明阿莫西林修饰的肽与风险单体型的两个成分结合,以刺激 DILI 患者的 T 细胞,并描述了在 HLA 结合肽序列中亲核赖氨酸残基的位置的重要性。